• Kyongbo Pharmaceutical swung to a third-quarter 2026 net loss of KRW 867 million from a year-earlier profit of KRW 3.03 billion.
• Operating profit fell 78.9% year over year to KRW 100 million.
• Revenue declined 1.2% year over year to KRW 66.16 billion.
• For January-September 2026, revenue rose 7.6% to KRW 207.5 billion.
• Nine-month net profit increased 156.4% to KRW 1.58 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyongbo Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800523), on October 30, 2026, and is solely responsible for the information contained therein.